Skip to main content

DIAGNOS Receives Health Canada Medical Device Licence for CARA System, Bringing AI-Assisted Retinal Image Analysis to Canadian Optometrists

Written by Customer Service on . Posted in Public Companies.

BROSSARD, Quebec, July 27, 2026 (GLOBE NEWSWIRE) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that, on July 23, 2026, it has received a Health Canada Medical Device Licence authorizing the commercialization of its CARA System in Canada.

CARA System technology integrates AI-powered analysis modules within a single clinician-controlled workflow:

  • CARA-AMDdetect – Age-related macular degeneration detection
  • CARA-DR – Diabetic retinopathy detection
  • CARA-MVA – Retinal microvascular analysis
  • CARA-Enhancement – Advanced retinal image enhancement
  • CARA-CWS – Clinician WorkSpace for annotations

By combining image enhancement, explainable AI findings, fundus indicators and retinal vascular analytics, CARA helps clinicians unlock more clinically relevant information from every fundus photograph while ensuring that the optometrist remains in full control of every clinical decision.

To our knowledge, CARA is one the first Canadian AI-retinal image analysis platform developed specifically for the Optometry sector to be granted a Class II medical device licence by Health Canada. This authorization allows us to fully deliver our services to IRIS The Visual Group (refer to announcement dated June 7, 2022) and to deploy our marketing strategy to address the Canadian optometry market.

Nowadays, retina of the eye photography is routinely incorporated into optometry clinical workflows practices from both independent optometry practices and major eye care networks. Using advanced image enhancement and explainable artificial intelligence, CARA System uses every pixel of a fundus photograph to provide the optometrist with objective analytical insights related to retinal conditions that may not have been readily apparent.

“For more than a decade, DIAGNOS has been working with AI for retinal image analysis through collaborations with clinicians and healthcare organizations around the world, driven by one mission – to help prevent avoidable blindness,” said André Larente, President and Chief Executive Officer of DIAGNOS.“

“Health Canada’s authorization of the CARA System is an important achievement not only for DIAGNOS, but also for Quebec’s innovation ecosystem,” said Philippe Couillard, chairman of the board of directors of DIAGNOS. “Successfully developing artificial intelligence for regulated medical devices requires scientific excellence, clinical rigor and exceptional perseverance. I am proud that Quebec-based companies can develop world-class medical technologies, meet one of the world’s most demanding regulatory standards, and compete successfully on the international stage.”

“We are excited to bring CARA System to Canadian optometrists, unlocking the full clinical value of every fundus image through explainable AI. CARA System transforms routinely acquired retinal images into deeper clinical insights while ensuring clinicians remain at the center of every clinical decision,” said Yves-Stephane Couture, Chief Operating Officer of DIAGNOS.

Regulatory compliance update

CARA System is by nature a medical device which, in most markets, requires proper local regulatory commercialization authorization. Meeting regulatory compliance for medical devices ensures public safety. Management focus remains obtaining regulatory commercialization clearance for CARA System from the Saudi Arabia Food & Drug Authority (SFDA) and the United States Food and Drug Administration (US-FDA).

  • Saudi Arabia: As stated in the Management Discussion and Analysis report (MD&A) dated June 11, 2026, available on www.diagnos.com  and www.sedarplus.com, DIAGNOS formally submitted CARA System for marketing approval with the SFDA. Since then, the Corporation is addressing additional queries received from the SFDA.
     
  • USA: As stated in MD&A dated June 11, 2026, available on www.diagnos.com  and www.sedarplus.com, the legacy version of CARA, as a Medical Image Management and Processing System, remains cleared for commercialization in the U.S. With the help of our U.S. based regulatory consultant, our goal is to be able to submit the commercialization application of CARA System to the FDA before the end of September 2026.

About DIAGNOS
DIAGNOS is a publicly traded Canadian corporation dedicated to early detection of certain critical eye-related health problems. By leveraging Artificial Intelligence, DIAGNOS aims to provide more information to healthcare clinicians to enhance diagnostic accuracy, streamline workflows, and improve patient outcomes on a global scale.

Additional information is available at www.diagnos.com and www.sedarplus.com.

This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CONTACT: For further information, please contact:

Mr. André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 ext. 224
alarente@diagnos.ca

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.